CS276453B6 - Process for preparing surface antigen hepatitis b - Google Patents

Process for preparing surface antigen hepatitis b Download PDF

Info

Publication number: CS276453B6
Authority: CS; Czechoslovakia
Prior art keywords: dna; dna fragment; fragment; yeast; plasmid
Prior art date: 1985-11-26

Application number

CS868641A

Other languages

Czech (cs)

English (en)

Other versions

CS864186A3 (en

Inventor

Juerg Friedrich Tschopp

James Michael Cregg

Michael Miller Harpold

Richard Gordon Buckholz

Original Assignee

Phillips Petroleum Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-11-26

Filing date

1986-11-26

Publication date

1992-06-17

1986-11-26 Application filed by Phillips Petroleum Co filed Critical Phillips Petroleum Co

1992-01-15 Publication of CS864186A3 publication Critical patent/CS864186A3/cs

1992-06-17 Publication of CS276453B6 publication Critical patent/CS276453B6/cs

Links

108091007433 antigens Proteins 0.000 title claims abstract description 31
239000000427 antigen Substances 0.000 title claims abstract description 28
102000036639 antigens Human genes 0.000 title claims abstract description 28
238000004519 manufacturing process Methods 0.000 title abstract description 9
208000006454 hepatitis Diseases 0.000 title description 2
231100000283 hepatitis Toxicity 0.000 title description 2
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 99
108020004414 DNA Proteins 0.000 claims abstract description 90
239000013612 plasmid Substances 0.000 claims abstract description 72
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 48
229910052799 carbon Inorganic materials 0.000 claims abstract description 48
208000002672 hepatitis B Diseases 0.000 claims abstract description 32
230000001105 regulatory effect Effects 0.000 claims abstract description 32
108091026890 Coding region Proteins 0.000 claims abstract description 9
239000012634 fragment Substances 0.000 claims description 95
108090000623 proteins and genes Proteins 0.000 claims description 58
240000004808 Saccharomyces cerevisiae Species 0.000 claims description 48
238000000034 method Methods 0.000 claims description 38
241000235648 Pichia Species 0.000 claims description 24
229920001184 polypeptide Polymers 0.000 claims description 22
102000004196 processed proteins & peptides Human genes 0.000 claims description 22
108090000765 processed proteins & peptides Proteins 0.000 claims description 22
239000001963 growth medium Substances 0.000 claims description 16
239000003550 marker Substances 0.000 claims description 13
108091028043 Nucleic acid sequence Proteins 0.000 claims description 11
238000002360 preparation method Methods 0.000 claims description 10
108700026244 Open Reading Frames Proteins 0.000 claims description 9
230000001580 bacterial effect Effects 0.000 claims description 8
210000000349 chromosome Anatomy 0.000 claims description 7
230000010076 replication Effects 0.000 claims description 6
108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 5
238000013518 transcription Methods 0.000 claims description 5
230000035897 transcription Effects 0.000 claims description 5
238000012258 culturing Methods 0.000 claims description 4
230000001747 exhibiting effect Effects 0.000 claims description 4
108020004999 messenger RNA Proteins 0.000 claims description 3
239000002773 nucleotide Substances 0.000 claims description 3
125000003729 nucleotide group Chemical group 0.000 claims description 3
230000008488 polyadenylation Effects 0.000 claims description 3
230000003362 replicative effect Effects 0.000 claims description 3
241001515965 unidentified phage Species 0.000 claims description 3
230000005030 transcription termination Effects 0.000 claims description 2
238000002955 isolation Methods 0.000 abstract description 2
230000000754 repressing effect Effects 0.000 abstract 2
235000003642 hunger Nutrition 0.000 abstract 1
230000037351 starvation Effects 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 38
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 30
239000013598 vector Substances 0.000 description 23
241000235058 Komagataella pastoris Species 0.000 description 22
230000014509 gene expression Effects 0.000 description 22
102000004169 proteins and genes Human genes 0.000 description 22
108010025188 Alcohol oxidase Proteins 0.000 description 18
229920001817 Agar Polymers 0.000 description 17
239000008272 agar Substances 0.000 description 17
238000010276 construction Methods 0.000 description 16
230000012010 growth Effects 0.000 description 16
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 15
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 15
230000009466 transformation Effects 0.000 description 15
239000002245 particle Substances 0.000 description 14
241000588724 Escherichia coli Species 0.000 description 13
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
239000008103 glucose Substances 0.000 description 12
NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Substances [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 12
239000000243 solution Substances 0.000 description 12
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 11
239000000600 sorbitol Substances 0.000 description 11
230000002950 deficient Effects 0.000 description 10
239000000203 mixture Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
239000008188 pellet Substances 0.000 description 9
239000011537 solubilization buffer Substances 0.000 description 9
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
101150061183 AOX1 gene Proteins 0.000 description 8
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000000178 monomer Substances 0.000 description 8
101150069554 HIS4 gene Proteins 0.000 description 7
241000364057 Peoria Species 0.000 description 7
150000001413 amino acids Chemical class 0.000 description 7
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 7
238000011534 incubation Methods 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
102000004594 DNA Polymerase I Human genes 0.000 description 6
108010017826 DNA Polymerase I Proteins 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
241000700721 Hepatitis B virus Species 0.000 description 6
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
150000003138 primary alcohols Chemical class 0.000 description 6
230000008929 regeneration Effects 0.000 description 6
238000011069 regeneration method Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
0 CCC(CC)*1=CC1C1C=CC*1 Chemical compound CCC(CC)*1=CC1C1C=CC*1 0.000 description 5
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
239000011521 glass Substances 0.000 description 5
230000037361 pathway Effects 0.000 description 5
ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
239000007222 ypd medium Substances 0.000 description 5
241000222120 Candida <Saccharomycetales> Species 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
108010067193 Formaldehyde transketolase Proteins 0.000 description 4
239000011324 bead Substances 0.000 description 4
229960002685 biotin Drugs 0.000 description 4
235000020958 biotin Nutrition 0.000 description 4
239000011616 biotin Substances 0.000 description 4
238000010790 dilution Methods 0.000 description 4
239000012895 dilution Substances 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
239000008223 sterile water Substances 0.000 description 4
230000001131 transforming effect Effects 0.000 description 4
238000011282 treatment Methods 0.000 description 4
239000004475 Arginine Substances 0.000 description 3
239000005715 Fructose Substances 0.000 description 3
229930091371 Fructose Natural products 0.000 description 3
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 3
239000000020 Nitrocellulose Substances 0.000 description 3
239000007983 Tris buffer Substances 0.000 description 3
229920004890 Triton X-100 Polymers 0.000 description 3
239000013504 Triton X-100 Substances 0.000 description 3
WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000006285 cell suspension Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
230000007547 defect Effects 0.000 description 3
239000008121 dextrose Substances 0.000 description 3
230000029087 digestion Effects 0.000 description 3
230000000694 effects Effects 0.000 description 3
239000000284 extract Substances 0.000 description 3
238000000605 extraction Methods 0.000 description 3
229930182830 galactose Natural products 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
239000002054 inoculum Substances 0.000 description 3
238000003780 insertion Methods 0.000 description 3
230000037431 insertion Effects 0.000 description 3
239000002609 medium Substances 0.000 description 3
244000005700 microbiome Species 0.000 description 3
229920001220 nitrocellulos Polymers 0.000 description 3
210000002381 plasma Anatomy 0.000 description 3
229940116357 potassium thiocyanate Drugs 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 3
210000005253 yeast cell Anatomy 0.000 description 3
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
101710191958 Amino-acid acetyltransferase Proteins 0.000 description 2
102000009042 Argininosuccinate Lyase Human genes 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
108060002716 Exonuclease Proteins 0.000 description 2
229940124872 Hepatitis B virus vaccine Drugs 0.000 description 2
101000695548 Homo sapiens Probable proline-tRNA ligase, mitochondrial Proteins 0.000 description 2
241001506991 Komagataella phaffii GS115 Species 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
102100028531 Probable proline-tRNA ligase, mitochondrial Human genes 0.000 description 2
241000223252 Rhodotorula Species 0.000 description 2
241000235070 Saccharomyces Species 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
238000002105 Southern blotting Methods 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
101150050575 URA3 gene Proteins 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
238000003556 assay Methods 0.000 description 2
229940098773 bovine serum albumin Drugs 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000001925 catabolic effect Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
230000037430 deletion Effects 0.000 description 2
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
102000013165 exonuclease Human genes 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
230000006698 induction Effects 0.000 description 2
239000007788 liquid Substances 0.000 description 2
238000005259 measurement Methods 0.000 description 2
230000035772 mutation Effects 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
108010085336 phosphoribosyl-AMP cyclohydrolase Proteins 0.000 description 2
230000002285 radioactive effect Effects 0.000 description 2
238000005215 recombination Methods 0.000 description 2
230000001172 regenerating effect Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
239000001488 sodium phosphate Substances 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000009987 spinning Methods 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
108010082737 zymolyase Proteins 0.000 description 2
BHKKSKOHRFHHIN-MRVPVSSYSA-N 1-[[2-[(1R)-1-aminoethyl]-4-chlorophenyl]methyl]-2-sulfanylidene-5H-pyrrolo[3,2-d]pyrimidin-4-one Chemical compound N[C@H](C)C1=C(CN2C(NC(C3=C2C=CN3)=O)=S)C=CC(=C1)Cl BHKKSKOHRFHHIN-MRVPVSSYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
101150076489 B gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
108010023063 Bacto-peptone Proteins 0.000 description 1
238000009010 Bradford assay Methods 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
101100328086 Caenorhabditis elegans cla-1 gene Proteins 0.000 description 1
BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
241000283707 Capra Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
238000007400 DNA extraction Methods 0.000 description 1
101100246753 Halobacterium salinarum (strain ATCC 700922 / JCM 11081 / NRC-1) pyrF gene Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
101000976075 Homo sapiens Insulin Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
241000235649 Kluyveromyces Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
KWYHDKDOAIKMQN-UHFFFAOYSA-N N,N,N',N'-tetramethylethylenediamine Chemical compound CN(C)CCN(C)C KWYHDKDOAIKMQN-UHFFFAOYSA-N 0.000 description 1
108090000854 Oxidoreductases Proteins 0.000 description 1
101150065207 P40 gene Proteins 0.000 description 1
229920002562 Polyethylene Glycol 3350 Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
241000288906 Primates Species 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
KIDHWZJUCRJVML-UHFFFAOYSA-N Putrescine Natural products NCCCCN KIDHWZJUCRJVML-UHFFFAOYSA-N 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000235346 Schizosaccharomyces Species 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
241000517713 Tremaster Species 0.000 description 1
239000007984 Tris EDTA buffer Substances 0.000 description 1
241001105470 Valenzuela Species 0.000 description 1
241000700605 Viruses Species 0.000 description 1
QOTAEASRCGCJDN-UHFFFAOYSA-N [C].CO Chemical compound [C].CO QOTAEASRCGCJDN-UHFFFAOYSA-N 0.000 description 1
150000001447 alkali salts Chemical class 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
230000003698 anagen phase Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
239000005388 borosilicate glass Substances 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
229910001424 calcium ion Inorganic materials 0.000 description 1
229940041514 candida albicans extract Drugs 0.000 description 1
230000010261 cell growth Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000002759 chromosomal effect Effects 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000005336 cracking Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
239000013024 dilution buffer Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000006862 enzymatic digestion Effects 0.000 description 1
ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000012224 gene deletion Methods 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
238000002649 immunization Methods 0.000 description 1
230000003053 immunization Effects 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
230000010354 integration Effects 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
239000008101 lactose Substances 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
239000013642 negative control Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000010979 pH adjustment Methods 0.000 description 1
229940050929 polyethylene glycol 3350 Drugs 0.000 description 1
-1 polypropylene Polymers 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000006798 recombination Effects 0.000 description 1
230000014493 regulation of gene expression Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
238000012216 screening Methods 0.000 description 1
239000006152 selective media Substances 0.000 description 1
239000013605 shuttle vector Substances 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000012064 sodium phosphate buffer Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
238000010998 test method Methods 0.000 description 1
230000002103 transcriptional effect Effects 0.000 description 1
YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1
239000003643 water by type Substances 0.000 description 1
238000001262 western blot Methods 0.000 description 1
239000012138 yeast extract Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
- C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
General Health & Medical Sciences (AREA)
Mycology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Virology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Saccharide Compounds (AREA)
Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Beans For Foods Or Fodder (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

CS868641A 1985-11-26 1986-11-26 Process for preparing surface antigen hepatitis b CS276453B6 (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/801,713 US4895800A (en)	1985-11-26	1985-11-26	Yeast production of hepatitis B surface antigen

Publications (2)

Publication Number	Publication Date
CS864186A3 CS864186A3 (en)	1992-01-15
CS276453B6 true CS276453B6 (en)	1992-06-17

Family

ID=25181867

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CS868641A CS276453B6 (en)	1985-11-26	1986-11-26	Process for preparing surface antigen hepatitis b

Country Status (28)

Country	Link
US (1)	US4895800A (fr)
EP (1)	EP0226846B1 (fr)
JP (1)	JPH0763372B2 (fr)
KR (1)	KR920004050B1 (fr)
CN (1)	CN86107885A (fr)
AT (1)	ATE92527T1 (fr)
AU (1)	AU583683B2 (fr)
CA (1)	CA1285895C (fr)
CS (1)	CS276453B6 (fr)
DD (1)	DD252614A5 (fr)
DE (1)	DE3688831T2 (fr)
DK (1)	DK565186A (fr)
EG (1)	EG17949A (fr)
ES (1)	ES2058055T3 (fr)
FI (1)	FI95929C (fr)
HU (1)	HUT43112A (fr)
IE (1)	IE64519B1 (fr)
IL (1)	IL80754A (fr)
IN (1)	IN166428B (fr)
MX (1)	MX4334A (fr)
NO (1)	NO176025C (fr)
NZ (1)	NZ218286A (fr)
PH (2)	PH25941A (fr)
PL (1)	PL152882B1 (fr)
PT (1)	PT83819B (fr)
TW (1)	TW215457B (fr)
YU (1)	YU46031B (fr)
ZA (1)	ZA868601B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4777240A (en) *	1984-03-08	1988-10-11	Scripps Clinic And Research Foundation	SV40 expression vector containing HBxAg as an expression marker
GB8521496D0 (en) *	1985-08-29	1985-10-02	Ciba Geigy Ag	Repressible yeast promoters
US5135868A (en) *	1985-10-25	1992-08-04	Phillips Petroleum Company	Cultures of yeast of the genus Pichia altered by site selective genomic modification
US5032516A (en) *	1985-10-25	1991-07-16	Phillips Petroleum Company	Pichia pastoris alcohol oxidase II regulatory region
US4683293A (en) *	1986-10-20	1987-07-28	Phillips Petroleum Company	Purification of pichia produced lipophilic proteins
ATE91304T1 (de) *	1987-02-27	1993-07-15	Merck & Co Inc	Verfahren zur herstellung des pres 1/s2/shepatitis-b-antigens aus hefe.
US5026828A (en) *	1987-02-27	1991-06-25	Merck & Co., Inc.	Method of purifying recombinant pres-1/S-2/S/S hepatitis B antigen from yeast
ATE93891T1 (de) *	1987-03-09	1993-09-15	Merck & Co Inc	Reinigung von rekombiniertem hepatitis-boberfl\|chen-antigen.
EP0300213A1 (fr) *	1987-06-22	1989-01-25	Hexal-Pharma Gentechnik GmbH & Co. KG	Particules immunogènes peptidiques virales d'hépatite A
US5011915A (en) *	1987-10-26	1991-04-30	Merck & Co., Inc.	Process for purifying recombinant hepatitis antigens
EP0314240A3 (fr) *	1987-10-26	1990-03-28	Merck & Co. Inc.	Procédé de purification d'antigènes recombinants d'hépatite
US5004688A (en) *	1988-04-15	1991-04-02	Phillips Petroleum Company	Purification of hepatitis proteins
IL89989A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human interleukin-2 in methylotrophic yeasts
IL90021A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Process for the production of interferon
NZ228774A (en) *	1988-04-25	1991-05-28	Phillips Petroleum Co	Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
IL89992A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of human serum albumin in methylotrophic yeasts
IL89993A0 (en) *	1988-04-25	1989-12-15	Phillips Petroleum Co	Expression of the hiv 24kda gag protein in methylotrophic yeasts
IL90161A0 (en) *	1988-05-13	1989-12-15	Phillips Petroleum Co	Expression of hepatitis b s and pres2 proteins in methylotrophic yeasts
IL91765A0 (en) *	1988-09-26	1990-06-10	Salk Inst Biotech Ind	Mixed feed recombinant yeast fermentation
AU5196290A (en) *	1989-02-13	1990-09-05	Salk Institute Biotechnology/Industrial Associates, Inc., The	Production of superoxide dismutase in pichia pastoris yeast cells
US6197548B1 (en)	1990-04-02	2001-03-06	Medeva Pharma Limited	Transformed Pichia expressing the pertactin antigen
US5612198A (en) *	1990-09-04	1997-03-18	The Salk Institute	Production of insulin-like growth factor-1 in methylotrophic yeast cells
EP0548267A4 (en) *	1990-09-04	1994-11-23	Salk Inst Biotech Ind	Production of insulin-like growth factor-1 in methylotrophic yeast cells
CU22290A1 (es) *	1990-10-08	1995-01-31	Cigb	Procedimiento para la obtencion de antigeno de superficie del virus de la hepatitis b de superior capacidad inmunoganica y su uso en un preparado vacunal
US5268273A (en) *	1990-12-14	1993-12-07	Phillips Petroleum Company	Pichia pastoris acid phosphatase gene, gene regions, signal sequence and expression vectors comprising same
EP0491077A1 (fr) *	1990-12-19	1992-06-24	Medeva Holdings B.V.	Composition utilisée comme agent thérapeutique contre des maladies hépatiques chroniques
WO1992013951A1 (fr) *	1991-02-04	1992-08-20	The Salk Institute Biotechnology/Industrial Associates, Inc.	Production de serumalbumine humaine dans des cellules de levure methylotrophique
CA2063890C (fr) *	1991-03-27	2007-03-13	Masami Miura	Promoteur aox2 mutant, microorganisme le renfermant, methode pour le preparer et production d'une proteine heterologue a l'aide de ce microorganisme
ATE220105T1 (de) *	1991-04-01	2002-07-15	Merck & Co Inc	Gene, die die proteolytische aktivitaet von pichia beeinflussen und deren verwendung
CA2058820C (fr) *	1991-04-25	2003-07-15	Kotikanyad Sreekrishna	Cassettes d'expression et vecteurs pour la secretion de serum albumine humaine dans des cellules pichia pastoris
US5330901A (en) *	1991-04-26	1994-07-19	Research Corporation Technologies, Inc.	Expression of human serum albumin in Pichia pastoris
US5850025A (en) *	1991-09-19	1998-12-15	Sibia Neurosciences, Inc.	Protection of plants against plant pathogens
SG48365A1 (en)	1992-05-23	1998-04-17	Smithkline Beecham Biolog	Combined vaccines comprising hepatitis b surface antigen and other antigens
CA2138997C (fr)	1992-06-25	2003-06-03	Jean-Paul Prieels	Composition vaccinale qui contient des adjuvants
JPH06209763A (ja) *	1993-01-13	1994-08-02	Green Cross Corp:The	変異株
US5945275A (en) *	1994-10-18	1999-08-31	Corvas International, Inc.	Nematode-extracted anticoagulant protein
CA2202351A1 (fr) *	1994-10-18	1996-04-25	George Phillip Vlasuk	Proteines anticoagulantes et inhibiteurs de la serine-protease extraits de nematodes
US5866542A (en) *	1994-10-18	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5866543A (en) *	1995-06-05	1999-02-02	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5872098A (en) *	1995-06-05	1999-02-16	Corvas International, Inc.	Nematode-extracted anticoagulant protein
EP0788546B9 (fr) *	1994-10-18	2007-06-13	Dendreon Corporation	Proteines anticoagulantes et inhibiteurs de la serine-protease extraits de nematodes
US5863894A (en) *	1995-06-05	1999-01-26	Corvas International, Inc.	Nematode-extracted anticoagulant protein
US5955349A (en) *	1996-08-26	1999-09-21	Zymogenetics, Inc.	Compositions and methods for producing heterologous polypeptides in Pichia methanolica
US5716808A (en) *	1995-11-09	1998-02-10	Zymogenetics, Inc.	Genetic engineering of pichia methanolica
GB9623233D0 (en)	1996-11-07	1997-01-08	Smithkline Beecham Biolog	Vaccine composition
KR100629028B1 (ko)	1998-10-16	2006-09-26	글락소스미스클라인 바이오로지칼즈 에스.에이.	애쥬번트 시스템 및 백신
UA79735C2 (uk) *	2000-08-10	2007-07-25	Глаксосмітклайн Байолоджікалз С.А.	Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
RU2201452C2 (ru) *	2000-12-28	2003-03-27	Общество с ограниченной ответственностью "Биотех"	Рекомбинантная плазмидная днк рнвs, обеспечивающая биосинтез поверхностного антигена вируса гепатита в, способ конструирования плазмиды, штамм дрожжей pichia pastoris ps103 (phbs) - продуцент указанного антигена
DE60335602D1 (de) *	2002-12-18	2011-02-17	Roche Diagnostics Gmbh	Rekombinante Desoxyribonuclease I aus Rinder-Pankreas mit hoher spezifischer Aktivität
ATE387494T1 (de) *	2002-12-20	2008-03-15	Hoffmann La Roche	Hitzelabile desoxyribonuklease i-varianten
EP1460425A1 (fr) *	2003-03-17	2004-09-22	Boehringer Mannheim Gmbh	Enzymes déglycosylés pour conjugués
ES2337684T3 (es) *	2003-12-05	2010-04-28	F. Hoffmann-La Roche Ag	Carboxipeptidasa b recombinante y su purificacion.
AU2006291780B2 (en) *	2005-09-14	2011-12-08	F. Hoffmann-La Roche Ag	Cleavage of precursors of insulins by a variant of trypsin
EP2441469A1 (fr)	2006-03-14	2012-04-18	Oregon Health and Science University	Méthode pour produire une reponse contre la tuberculose
JP5814507B2 (ja)	2006-09-07	2015-11-17	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
JP4216875B2 (ja) *	2006-09-29	2009-01-28	株式会社東芝	メタノール応答性プロモーター、プロモーターと外来遺伝子を発現可能な様式で連結した融合遺伝子、ベクター、形質転換体、およびタンパク質の生産方法
WO2008106551A2 (fr)	2007-02-28	2008-09-04	The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv.	Polypeptides brachyury et procédés d'utilisation.
JP2010525035A (ja)	2007-05-02	2010-07-22	グラクソスミスクラインバイオロジカルズソシエテアノニム	ワクチン
WO2009143524A2 (fr)	2008-05-23	2009-11-26	The Regents Of The University Of Michigan	Vaccins à nanoémulsion
WO2010017209A2 (fr)	2008-08-04	2010-02-11	The Government Of The Usa As Represented By The Secretary Of The Department Of Health And Human Services	Région proximale de membrane de gp41 de vih ancrée à la couche lipidique d’un vaccin de particule de type viral
WO2010099472A2 (fr)	2009-02-27	2010-09-02	The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services	Polypeptides spanx-b et leur utilisation
WO2011047340A1 (fr)	2009-10-16	2011-04-21	The United States Of America, As Represented By The Secretary, Department Of Health & Human Services	Insertion de gènes étrangers dans le virus de la rubéole et leur expression stable dans un vaccin viral vivant atténué
GB201105981D0 (en)	2011-04-08	2011-05-18	Glaxosmithkline Biolog Sa	Novel process
US9566329B2 (en)	2012-04-06	2017-02-14	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Live, attenuated rubella vector to express vaccine antigens
WO2014043518A1 (fr)	2012-09-14	2014-03-20	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Protéine brachyury, vecteurs non levure, non poxvirus, codant pour la protéine brachyury, et leur utilisation
WO2014135651A1 (fr)	2013-03-08	2014-09-12	Crucell Holland B.V.	Vaccin acellulaire contre la coqueluche
EP4137150A1 (fr)	2015-08-03	2023-02-22	The United States of America, as represented by the Secretary, Department of Health and Human Services	Mutants de délétion de la protéine brachyury, vecteurs sans levure codant pour les mutants de délétion de la protéine brachyury, et leur utilisation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2480779B2 (fr) *	1979-08-30	1986-07-18	Anvar	Vecteur contenant une sequence nucleotidique de l'antigene de surface du virus de l'hepatite b et procede de fabrication d'une molecule immunogene mettant en oeuvre ce vecteur
GB2055847A (en) *	1979-07-30	1981-03-11	Bull F G	Process for the production of carrier particles
US4769238A (en) *	1981-08-04	1988-09-06	The Regents Of The University Of California	Synthesis of human virus antigens by yeast
US4803164A (en) *	1981-08-31	1989-02-07	Genentech, Inc.	Preparation of hepatitis b surface antigen in yeast
NZ201705A (en) *	1981-08-31	1986-03-14	Genentech Inc	Recombinant dna method for production of hepatitis b surface antigen in yeast
DE3381566D1 (de) *	1982-08-16	1990-06-21	Agency Science & Tech	Hepatitis-b-virus-gen enthaltendes rekombinantes plasmid, mit diesem rekombinanten plasmid transformierte hefe und herstellung von hepatitis-b-virus-oberflaechenantigen.
IL69202A (en) *	1982-09-08	1991-08-16	Smith Kline Rit	Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
US4510245A (en) *	1982-11-18	1985-04-09	Chiron Corporation	Adenovirus promoter system
CA1341302C (fr) *	1983-02-22	2001-10-09	Rae Lyn Burke	Systemes d'expression de la levure avec vecteurs ayant des promoteurs de gapdh ou pyk et synthese de proteine etrangere
US4515714A (en) *	1983-03-09	1985-05-07	Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute	Method for purification of hepatitis B virus surface antigen
EP0135435A3 (fr) *	1983-08-22	1987-03-25	Merck & Co. Inc.	HBsAg immunogénique dérivé de levure transformée
US4614793A (en) *	1983-10-14	1986-09-30	Merck & Co., Inc.	Hepatitis A--subunit antigen
JPS60196185A (ja) *	1984-03-19	1985-10-04	Chemo Sero Therapeut Res Inst	形質転換酵母の培養方法
US4837148A (en) *	1984-10-30	1989-06-06	Phillips Petroleum Company	Autonomous replication sequences for yeast strains of the genus pichia
US4855231A (en) *	1984-10-30	1989-08-08	Phillips Petroleum Company	Regulatory region for heterologous gene expression in yeast
US4879231A (en) *	1984-10-30	1989-11-07	Phillips Petroleum Company	Transformation of yeasts of the genus pichia
US4882279A (en) *	1985-10-25	1989-11-21	Phillips Petroleum Company	Site selective genomic modification of yeast of the genus pichia

1985
- 1985-11-26 US US06/801,713 patent/US4895800A/en not_active Expired - Lifetime
1986
- 1986-07-10 CA CA000513467A patent/CA1285895C/fr not_active Expired - Lifetime
- 1986-11-12 IN IN819/CAL/86A patent/IN166428B/en unknown
- 1986-11-12 ZA ZA868601A patent/ZA868601B/xx unknown
- 1986-11-12 MX MX433486A patent/MX4334A/es unknown
- 1986-11-13 NZ NZ218286A patent/NZ218286A/en unknown
- 1986-11-14 IE IE302186A patent/IE64519B1/en not_active IP Right Cessation
- 1986-11-19 AU AU65384/86A patent/AU583683B2/en not_active Expired
- 1986-11-24 PH PH34520A patent/PH25941A/en unknown
- 1986-11-24 EG EG733/86A patent/EG17949A/xx active
- 1986-11-24 CN CN198686107885A patent/CN86107885A/zh active Pending
- 1986-11-25 HU HU864873A patent/HUT43112A/hu unknown
- 1986-11-25 DK DK565186A patent/DK565186A/da not_active Application Discontinuation
- 1986-11-25 AT AT86116302T patent/ATE92527T1/de active
- 1986-11-25 IL IL80754A patent/IL80754A/xx unknown
- 1986-11-25 DD DD29662586A patent/DD252614A5/de unknown
- 1986-11-25 DE DE86116302T patent/DE3688831T2/de not_active Expired - Lifetime
- 1986-11-25 ES ES86116302T patent/ES2058055T3/es not_active Expired - Lifetime
- 1986-11-25 NO NO864704A patent/NO176025C/no not_active IP Right Cessation
- 1986-11-25 FI FI864791A patent/FI95929C/fi not_active IP Right Cessation
- 1986-11-25 EP EP86116302A patent/EP0226846B1/fr not_active Expired - Lifetime
- 1986-11-25 YU YU201386A patent/YU46031B/sh unknown
- 1986-11-25 KR KR1019860010018A patent/KR920004050B1/ko not_active Expired
- 1986-11-25 JP JP61280567A patent/JPH0763372B2/ja not_active Expired - Fee Related
- 1986-11-26 CS CS868641A patent/CS276453B6/cs unknown
- 1986-11-26 PL PL1986262598A patent/PL152882B1/pl unknown
- 1986-11-26 PT PT83819A patent/PT83819B/pt not_active IP Right Cessation
- 1986-12-01 TW TW075105699A patent/TW215457B/zh active
1987
- 1987-11-06 PH PH36040A patent/PH25539A/en unknown

Also Published As

Publication number	Publication date
DD252614A5 (de)	1987-12-23
ATE92527T1 (de)	1993-08-15
IL80754A0 (en)	1987-02-27
DE3688831T2 (de)	1993-11-25
DK565186A (da)	1987-05-27
FI95929B (fi)	1995-12-29
FI95929C (fi)	1996-04-10
PL152882B1 (en)	1991-02-28
YU201386A (en)	1988-10-31
EP0226846B1 (fr)	1993-08-04
KR920004050B1 (ko)	1992-05-23
US4895800A (en)	1990-01-23
NO864704D0 (no)	1986-11-25
DK565186D0 (da)	1986-11-25
PT83819B (pt)	1988-10-14
AU583683B2 (en)	1989-05-04
FI864791L (fi)	1987-05-27
IN166428B (fr)	1990-05-05
JPS62190085A (ja)	1987-08-20
ZA868601B (en)	1987-06-24
IE64519B1 (en)	1995-08-09
AU6538486A (en)	1987-05-28
PT83819A (en)	1986-12-01
PH25539A (en)	1991-07-24
NO176025B (no)	1994-10-10
KR870005099A (ko)	1987-06-04
EG17949A (en)	1991-03-30
JPH0763372B2 (ja)	1995-07-12
TW215457B (fr)	1993-11-01
CS864186A3 (en)	1992-01-15
HUT43112A (en)	1987-09-28
IE863021L (en)	1987-05-26
IL80754A (en)	1993-03-15
NO176025C (no)	1995-01-18
NZ218286A (en)	1991-07-26
PL262598A1 (en)	1987-09-21
ES2058055T3 (es)	1994-11-01
EP0226846A1 (fr)	1987-07-01
YU46031B (sh)	1992-12-21
PH25941A (en)	1991-12-19
CA1285895C (fr)	1991-07-09
CN86107885A (zh)	1987-09-23
DE3688831D1 (de)	1993-09-09
MX4334A (es)	1993-12-01
FI864791A0 (fi)	1986-11-25

Publication	Publication Date	Title
CS276453B6 (en)	1992-06-17	Process for preparing surface antigen hepatitis b
US4855231A (en)	1989-08-08	Regulatory region for heterologous gene expression in yeast
Hitzeman et al.	1983	Expression of hepatitis B virus surface antigen in yeast
EP0226752B1 (fr)	1993-12-15	Procédé pour une expression supérieure de polypeptides dans une levure du genre Pichia
EP0414374B1 (fr)	1997-10-08	Antigènes ainsi que les méthodes pour leur préparation
JP2614314B2 (ja)	1997-05-28	メチロトロフィック酵母におけるＢ型肝炎ＳおよびｐｒｅＳ▲下２▼タンパク質の発現
US5166329A (en)	1992-11-24	DNA encoding the alcohol oxidase 2 gene of yeast of the genus Pichia
HK1003032B (en)	1998-09-30	Novel antigens and methods for their preparation
AU605036B2 (en)	1991-01-03	Expression of hepatitis B2 pres protein in methylothrophic yeasts
EP0389377A1 (fr)	1990-09-26	Excrétion des protéines des cellules de levure
KR900005534B1 (ko)	1990-07-31	복합 프로모터를 이용한 효모 발현 벡터에 의한 b형 간염 바이러스 표면항원들의 제조방법
Sugden	1985	Molecular and Physiological Studies on Yeast and Fungal Protease Genes and Their Mutants
IE83234B1 (en)	2004-01-14	DNA fragment encoding an AOX